GLP-3R Explained: Retatrutide and the Glucagon Receptor

Research summary. GLP-3R is a common label for retatrutide, a synthetic peptide characterized in published research as a triple receptor agonist with affinity for the GLP-1, GIP, and glucagon receptors. In receptor-binding studies, retatrutide engaged the glucagon receptor as one of its three targets. This summarizes published pharmacology of a research material; it is not guidance for any use.

Author: Nox Amino Research Team Reviewed by: the Nox Amino Research Team Published: July 6, 2026 · Updated: July 6, 2026 Editorial methodology: /learn/editorial-standards

Research Use Only (RUO). All materials referenced on this page are intended exclusively for laboratory research and analytical use. They are not drugs, dietary supplements, or articles for human or veterinary consumption, and nothing here constitutes medical advice, a therapeutic claim, or instructions for use in or on the body. Statements below describe published third-party references (the New England Journal of Medicine and ClinicalTrials.gov) in their own terms; they are not claims about outcomes for any reader. See our Certificates of Analysis for identity and purity data on stocked reference materials.

What "GLP-3R" refers to

"GLP-3R" is an informal marketplace nickname for retatrutide, a synthetic peptide that published pharmacology characterized as a single-molecule triple receptor agonist. The label is shorthand for the compound engaging three receptors at once; it is not an official receptor name or pharmacological class. In the peer-reviewed literature and on ClinicalTrials.gov the same material is called retatrutide, and its development code was LY3437943.

The "3R" in the nickname points to the three receptors the published characterization named. Because the peptide's most-discussed feature is that trio of targets — one more than earlier dual agonists — the "GLP-3R" shorthand circulated informally. Throughout this page the compound is treated strictly as a research reference material, and every statement describes what the cited literature reported, in the past tense.

The three receptors, from the published literature

In the New England Journal of Medicine, Jastreboff and colleagues described retatrutide as an "agonist of the glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide 1 (GLP-1), and glucagon receptors" (Jastreboff et al., NEJM 2023; PMID 37366315). Those three receptors are the basis of the triple-agonist classification:

GLP-1 receptor — the glucagon-like peptide-1 receptor, a target shared with several earlier characterized peptides.
GIP receptor — the glucose-dependent insulinotropic polypeptide receptor.
Glucagon receptor — the receptor engaged by the hormone glucagon; its inclusion is what distinguished retatrutide's published profile from dual GLP-1/GIP agonists.

The glucagon receptor is the third target the "GLP-3R" nickname alludes to. In the reported receptor-binding characterization, retatrutide engaged the glucagon receptor as one of its three targets alongside the GLP-1 and GIP receptors. This article describes that receptor classification only, exactly as the literature framed it, and makes no statement about any physiological result.

What "receptor activation" means in an assay context

In pharmacology, an agonist is a molecule that binds a receptor and elicits a measurable response at it, whereas an antagonist binds and blocks it. Whether a molecule is an agonist and how strongly it engages a receptor are properties measured in vitro — in binding assays and cell-based signaling assays — and reported as parameters such as binding affinity and potency.

When the literature says retatrutide was an agonist at the GLP-1, GIP, and glucagon receptors, that is a description of these laboratory measurements: the molecule bound each receptor and produced a signal in the assay system. It is a neutral, benchtop characterization of the compound's targets. It is not a claim about anything happening in a human or animal body, and nothing here should be read as such. Receptor-level engagement measured in an assay and any outcome in a living subject are distinct questions, and only the former is in scope for a research-reagent explainer.

Why the compound is stocked as a research reference material

Retatrutide (GLP-3R) is stocked as a research reference material because its receptor pharmacology and trial classification are documented in the primary literature and on ClinicalTrials.gov, giving researchers a well-described peptide to reference. Its identity as a defined synthetic sequence, and the availability of batch-level analytical documentation, are what make it suitable to catalog as a reference standard for laboratory and analytical work.

For a compliant comparison of how retatrutide's published classification differs from related compounds, see Retatrutide vs Tirzepatide vs Semaglutide. The retatrutide reference material is listed in the Nox Amino catalog with a batch-specific Certificate of Analysis, and its identity — not any claim about use in or on the body — is the appropriate basis for selecting it.

How identity is confirmed on a COA

The identity of a peptide reference material such as retatrutide is confirmed analytically, not by its label alone, and the results are recorded on a batch-specific Certificate of Analysis (COA). Two techniques do most of the work:

HPLC (high-performance liquid chromatography) separates the sample and reports chromatographic purity — the percentage of the material that is the intended peptide versus related impurities.
Mass spectrometry measures the molecular weight and confirms it matches the expected value for the peptide's amino-acid sequence, establishing identity.

A COA that pairs an HPLC purity value with a mass-spec identity confirmation is the appropriate document for evaluating a reference material. For a step-by-step walkthrough of these reports, see How to Read a Peptide COA, and review published batch data on the Certificates of Analysis page.

References

Create a free account to view the COA-verified retatrutide (GLP-3R) reference material, access batch-specific analytical data, and see member pricing. → Create your account

This article cites the New England Journal of Medicine and ClinicalTrials.gov for informational and laboratory-research purposes only. Nox Amino sells research reagents and compounds intended for laboratory and analytical use only, not for human or animal consumption. Nothing on this page is medical advice or a therapeutic claim. Editorial methodology and review process: /learn/editorial-standards.

Frequently Asked Questions

What does GLP-3R stand for?

GLP-3R is an informal marketplace label for retatrutide, a synthetic peptide the published literature characterized as a single-molecule triple receptor agonist. The name is shorthand for the compound's engagement of three receptors rather than an official pharmacological class; the peer-reviewed literature and ClinicalTrials.gov refer to the material as retatrutide (also written LY3437943). It is stocked and described here as a research reference material only.

Is GLP-3R the same as retatrutide?

Yes. In practice GLP-3R and retatrutide (development code LY3437943) refer to the same synthetic peptide. GLP-3R is a colloquial nickname derived from its triple-agonist description, while retatrutide is the name used in the New England Journal of Medicine report by Jastreboff et al. (2023) and across ClinicalTrials.gov trial records such as the TRIUMPH program (NCT05929066). Both point to one research compound characterized in the published pharmacology literature.

Which receptors does retatrutide target?

Published pharmacology characterized retatrutide as an agonist of three receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. Jastreboff et al. described it in the New England Journal of Medicine (2023) as a single peptide with agonist activity at all three, which is why it is often labeled a triple receptor agonist. This is a description of receptor-binding classification, not a statement about any effect in a person or animal.

What does "triple agonist" mean?

An agonist is a molecule that binds a receptor and produces a response at it, in contrast to an antagonist that blocks it. A triple agonist is a single molecule characterized as an agonist at three distinct receptors; for retatrutide the published literature named the GLP-1, GIP, and glucagon receptors. The term describes receptor engagement measured in binding and signaling assays, not any downstream outcome in a living subject.

How is the identity of a GLP-3R (retatrutide) reference material verified?

Identity is verified analytically on a batch-specific Certificate of Analysis (COA), typically using high-performance liquid chromatography (HPLC) to report chromatographic purity and mass spectrometry to confirm the molecular weight matches the expected peptide sequence. The COA, not any claim about use in or on the body, is the appropriate basis for selecting a research reference material. You can review COA data on the /coas page and create a free account for batch-specific analytical data.